GHO Capital raises €975m in largest ever European private equity healthcare fund.
   

Europe’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.

Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.

Thicker than ever: The 21st edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.

Danish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.

The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
 
 

Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.

Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AG’s anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).

Swiss Lonza announced that CEO Marc Funk is leaving the company. Chairman Albert Baehny will take over as CEO on an ad interim basis until a successor is found.

Swiss-German biotech Vaximm is teaming up with Tokyo-based AI specialist NEC to advance personalised neoantigen cancer vaccines.